Serotype distribution of Streptococcus pneumoniae causing invasive disease in the Republic of Ireland.
Vickers, I Fitzgerald, M Murchan, S Cotter, S O'Flanagan, D Cafferkey, M Humphreys, H
Vickers, I
Fitzgerald, M
Murchan, S
Cotter, S
O'Flanagan, D
Cafferkey, M
Humphreys, H
Advisors
Editors
Other Contributors
Date
2011-05
Date Submitted
Keywords
Other Subjects
Subject Mesh
Adolescent
Adult
Aged
Aged, 80 and over
Anti-Bacterial Agents
Bacterial Typing Techniques
Cefotaxime
Child
Child, Preschool
Humans
Infant
Infant, Newborn
Ireland
Male
Microbial Sensitivity Tests
Middle Aged
Penicillins
Pneumococcal Infections
Pneumococcal Vaccines
Serotyping
Streptococcus pneumoniae
Vaccination
Young Adult
beta-Lactam Resistance
Adult
Aged
Aged, 80 and over
Anti-Bacterial Agents
Bacterial Typing Techniques
Cefotaxime
Child
Child, Preschool
Humans
Infant
Infant, Newborn
Ireland
Male
Microbial Sensitivity Tests
Middle Aged
Penicillins
Pneumococcal Infections
Pneumococcal Vaccines
Serotyping
Streptococcus pneumoniae
Vaccination
Young Adult
beta-Lactam Resistance
Planned Date
Start Date
Collaborators
Principal Investigators
Alternative Titles
Publisher
Abstract
The 7-valent pneumococcal conjugate vaccine (PCV7) was included in the routine infant immunization schedule in Ireland in September 2008. We determined the serotype of 977 S. pneumoniae isolates causing invasive disease between 2000-2002 and 2007-2008, assessed for the presence of the recently described serotype 6C and determined the susceptibility of isolates during 2007-2008 to penicillin and cefotaxime. Serotype 14 was the most common serotype during both periods and 7·7% of isolates previously typed as serotype 6A were serotype 6C. During 2000-2002 and 2007-2008, PCV7 could potentially have prevented 85% and 74% of invasive pneumococcal disease in the target population (i.e. children aged <2 years), respectively. The level of penicillin non-susceptibility was 17% in 2007-2008. Ongoing surveillance of serotypes is required to determine the impact of PCV7 in the Irish population and to assess the potential of new vaccines with expanded valency.
Language
en
ISSN
1469-4409
eISSN
ISBN
DOI
10.1017/S0950268810001743
PMID
20642870